V J Marder

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Short-term effects of air pollution: a panel study of blood markers in patients with chronic pulmonary disease
    Katharina Hildebrandt
    Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Institute of Epidemiology, Munich, Germany
    Part Fibre Toxicol 6:25. 2009
  2. ncbi Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke
    Victor J Marder
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles Orthopaedic Hospital, 2400 S Flower St, Los Angeles, California 90007, USA
    Stroke 37:2086-93. 2006
  3. ncbi Maximized hemostasis
    Victor J Marder
    Los Angeles Orthopaedic Hospital, University of California, Los Angeles School of Medicine, 90007, USA
    Thromb Haemost 87:555-6. 2002
  4. ncbi The interaction of dietary supplements with antithrombotic agents: scope of the problem
    Victor J Marder
    Division of Hematology/Medical Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90007, USA
    Thromb Res 117:7-13; discussion 39-42. 2005
  5. ncbi Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit
    V J Marder
    Vascular Medicine Program, Los Angeles Orthopaedic Hospital University of California, 90007, USA
    Thromb Haemost 86:739-45. 2001
  6. ncbi Foundation and sites of action of antithrombotic agents
    Victor J Marder
    Vascular Medicine Program, Los Angeles Orthopedic Hospital, and Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, CA, USA
    Best Pract Res Clin Haematol 17:3-22. 2004
  7. ncbi Cocaine and Buerger disease: is there a pathogenetic association?
    V J Marder
    Vascular Medicine Program, Orthopaedic Hospital, 2400 S Flower St, Los Angeles, CA 90007, USA
    Arch Intern Med 160:2057-60. 2000
  8. ncbi Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. THROMBO Research Investigators
    V J Marder
    Orthopaedic Hospital UCLA School of Medicine, Los Angeles, CA, USA
    Thromb Haemost 82:1412-6. 1999
  9. ncbi Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding
    S Sadeghi
    Vascular Medicine Program, Los Angeles Orthopedic Hospital, and David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90007, USA
    J Thromb Haemost 1:2621-5. 2003
  10. ncbi Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysis
    D Stewart
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Thromb Haemost 4:1575-9. 2006

Research Grants

  1. SAFER THROMBOLYTIC THERAPY USING PLASMIN
    Victor Marder; Fiscal Year: 2007
  2. Training for Academic Hematology
    Victor Marder; Fiscal Year: 2007

Collaborators

Detail Information

Publications30

  1. ncbi Short-term effects of air pollution: a panel study of blood markers in patients with chronic pulmonary disease
    Katharina Hildebrandt
    Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Institute of Epidemiology, Munich, Germany
    Part Fibre Toxicol 6:25. 2009
    ..abstract:..
  2. ncbi Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke
    Victor J Marder
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles Orthopaedic Hospital, 2400 S Flower St, Los Angeles, California 90007, USA
    Stroke 37:2086-93. 2006
    ..Information regarding the histological structure of thromboemboli that cause acute stroke provides insight into pathogenesis and clinical management...
  3. ncbi Maximized hemostasis
    Victor J Marder
    Los Angeles Orthopaedic Hospital, University of California, Los Angeles School of Medicine, 90007, USA
    Thromb Haemost 87:555-6. 2002
  4. ncbi The interaction of dietary supplements with antithrombotic agents: scope of the problem
    Victor J Marder
    Division of Hematology/Medical Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90007, USA
    Thromb Res 117:7-13; discussion 39-42. 2005
  5. ncbi Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit
    V J Marder
    Vascular Medicine Program, Los Angeles Orthopaedic Hospital University of California, 90007, USA
    Thromb Haemost 86:739-45. 2001
    ..These results suggest that plasmin is an effective, unique thrombolytic agent, distinguished from the plasminogen activators in current usage by its striking safety profile...
  6. ncbi Foundation and sites of action of antithrombotic agents
    Victor J Marder
    Vascular Medicine Program, Los Angeles Orthopedic Hospital, and Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, CA, USA
    Best Pract Res Clin Haematol 17:3-22. 2004
    ..In this review, we discuss mechanisms of hemostasis in relation to antithrombotic agents and results of clinical trials using these drugs...
  7. ncbi Cocaine and Buerger disease: is there a pathogenetic association?
    V J Marder
    Vascular Medicine Program, Orthopaedic Hospital, 2400 S Flower St, Los Angeles, CA 90007, USA
    Arch Intern Med 160:2057-60. 2000
    ....
  8. ncbi Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. THROMBO Research Investigators
    V J Marder
    Orthopaedic Hospital UCLA School of Medicine, Los Angeles, CA, USA
    Thromb Haemost 82:1412-6. 1999
    ..003 and p = 0.001, respectively). This is the first demonstration that a latex agglutination assay for D-dimer can be used to assess the prognostic risk of recurrent coronary thrombotic disease after myocardial infarction..
  9. ncbi Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding
    S Sadeghi
    Vascular Medicine Program, Los Angeles Orthopedic Hospital, and David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90007, USA
    J Thromb Haemost 1:2621-5. 2003
    ..These data indicate that in the rabbit, concomitant use of aspirin plus heparin does not affect the safety of a therapeutic dose of plasmin...
  10. ncbi Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysis
    D Stewart
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Thromb Haemost 4:1575-9. 2006
    ....
  11. ncbi Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential
    V J Marder
    Hematology Medical Oncology Division, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Thromb Haemost 8:433-44. 2010
    ..Whether direct fibrinolytics will provide clinical superiority in major thrombotic disorders over currently utilized indirect fibrinolytics such as tissue plasminogen activator remains to be determined...
  12. ncbi Current issues concerning thrombolytic therapy for acute myocardial infarction
    C H Hennekens
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 25:18S-22S. 1995
    ..Whether or not accelerated t-PA has a small advantage for mortality is less conclusive.(ABSTRACT TRUNCATED AT 250 WORDS)..
  13. ncbi Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin
    S Chan
    Vascular Medicine Program, Los Angeles Orthopaedic Hospital, Los Angeles, CA 90007, USA
    J Thromb Haemost 1:760-5. 2003
    ..However, the bolus injection of LMWH produced a very high blood anti-FXa level, which may have precluded rFVIIa effectiveness...
  14. ncbi Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results
    V J Marder
    Division of Hematology Medical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Thromb Haemost 10:985-91. 2012
    ..Plasmin is a direct-acting thrombolytic with a striking safety advantage over PA in preclinical models...
  15. ncbi Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators
    W Zareba
    Department of Medicine, University of Rochester Medical Center, NY 14642, USA
    Thromb Haemost 86:791-9. 2001
    ....
  16. ncbi Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin
    V J Marder
    Division of Hematology and Medical Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Thromb Haemost 9:364-73. 2011
    ..After more than 50 years, the field has come full circle, and plasmin as the thrombolytic agent and catheter use for local delivery of agent may represent a step forward in thrombolytic therapy...
  17. ncbi Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment
    S E Martin
    Hematology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Thromb Res 31:437-49. 1983
    ..This chain may possess critical features that mimic the optimal structure of vW protein that forms intercellular bridges and promotes agonist stimulation by WGA via membrane receptors...
  18. ncbi Proteasome-independent activation of nuclear factor kappaB in cytoplasmic extracts from human endothelial cells by Rickettsia rickettsii
    S K Sahni
    Department of Medicine, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    Infect Immun 66:1827-33. 1998
    ..rickettsii may interact with and activate host cell transcriptional machinery independently of the involvement of the proteasome or known signal transduction pathways...
  19. ncbi Cloning of guinea pig tissue factor cDNA: comparison of primary structure among six mammalian species
    R J Shi
    Department of Medicine, University of Rochester, School of Medicine and Dentistry, NY, USA
    Thromb Haemost 83:455-61. 2000
    ..We hypothesize that divergence at these regions contributes to the specificity and non-reciprocity of TF procoagulant activity between species...
  20. ncbi Acquired thrombophilic syndromes
    D Matei
    Vascular Medicine Program, Los Angeles Orthopaedic Hospital University of California at Los Angeles, Los Angeles, CA 90007, USA
    Blood Rev 15:31-48. 2001
    ..All of these factors can directly influence thrombus formation and/or the physiologic response to the thrombus.(1)..
  21. ncbi Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage
    Daphne Stewart
    Vascular Medicine Program, Los Angeles Orthopaedic Hospital, The David Geffen School of Medicine at UCLA, University of California Los Angeles, CA 90007, USA
    Blood 101:3002-7. 2003
    ..Plasmin has a 6-fold margin of safety, in contrast with TPA, which causes hemorrhage at thrombolytic dosages...
  22. ncbi Towards safer thrombolytic therapy
    Victor J Marder
    Department of Vascular Medicine, Los Angeles Orthopaedic Hospital, 2400 S Flower Street, Los Angeles, CA 90007, USA
    Semin Hematol 39:206-16. 2002
    ..Animal studies are fully consistent with this approach, which offers potential for achieving a truly regional thrombolytic treatment...
  23. ncbi Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis
    Reza Jahan
    Stroke 39:1613-5. 2008
    ..Recanalization was achieved rapidly after IA plasmin in 3 of 3 animals. CONCLUSIONS: We describe a new animal model of selective MCA occlusion documented by real-time angiography and used to demonstrate recanalization with IA plasmin...
  24. ncbi Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients
    Tareq S Harb
    Cardiology Unit, Department of Medicine, University of Rochester Medical Center, New York 14642, USA
    Am J Cardiol 91:1120-3. 2003
  25. ncbi Conference summary and recommendations for research
    Ahmed A K Hasan
    Thrombosis and Hemostasis Program, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda, MD 20892, USA
    Thromb Res 117:229-30. 2005
  26. ncbi Opinions and research priorities
    Henry I Bussey
    College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
    Thromb Res 117:155-69; discussion 170-4. 2005
  27. ncbi Use of thrombolytic therapy for acute myocardial infarction: effects of gender and age on treatment rates
    Karen L Kaplan
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Thromb Thrombolysis 13:21-6. 2002
    ..This study was undertaken to determine the relative rates of treatment of women vs. men and the elderly vs. younger subjects and to examine factors that might explain differences in treatment frequency...
  28. ncbi Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
    Valery V Novokhatny
    Biological Products Division, Bayer HealthCare, PO Box 13887, 85 TW Alexander Drive, Research Triangle Park, NC 27709, USA
    Trends Pharmacol Sci 25:72-5. 2004
    ..These results predict that plasmin will prove to be both superior to, and safer than, plasminogen activators in the dissolution of long, retracted blood clots in humans...
  29. ncbi History of hypertension and enhanced thrombogenic activity in postinfarction patients
    Yazid Y Fadl
    Cardiology Unit, Department of Medicine, University of Rochester Medical Center, Box 653, Rochester, NY 14642, USA
    Hypertension 41:943-9. 2003
    ..02, P=0.005) and nonhypertensive (hazard ratio=2.42, P=0.02) patients. Thus, patients after infarction with a history of hypertension have enhanced thrombogenic activity, which predisposes them to recurrent cardiac events...
  30. ncbi Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients
    James P Corsetti
    Department of Pathology and Laboratory Medicine, School of Medicine and Dentistry, University of Rochester, P.O. Box 626, 601 Elmwood Avenue, Rochester, NY, USA
    Atherosclerosis 171:351-8. 2003
    ....

Research Grants7

  1. SAFER THROMBOLYTIC THERAPY USING PLASMIN
    Victor Marder; Fiscal Year: 2007
    ..We hypothesize and anticipate that plasmin will provide clinically effective thrombolysis without an increased risk of bleeding . ..
  2. Training for Academic Hematology
    Victor Marder; Fiscal Year: 2007
    ....